Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1822]

ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients...

Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA

$ADMIRAL trial results: Gilteritinib versus salvage chemotherapy in patients with FLT3-mutated relapsed/refractory AML ( Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA )$

Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory...

Prof Walter Fiedler - University of Hamburg, Hamburg, Germany

$Selinexor plus cytarabine and idarubicin in patients with relapsed/refractory acute myeloid leukaemia ( Prof Walter Fiedler - University of Hamburg, Hamburg, Germany )$

ECHELON-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy...

Dr Andrea Gallamini - Centre Antoine Lacassagne, Nice, France

ECHELON-1 study 3 year update: Frontline brentuximab vedotin with chemotherapy for stage 3/4 classical Hodgkin lymphoma ( Dr Andrea Gallamini - Centre Antoine Lacassagne, Nice, France )

HORIZON update: Using melflufen to treat RRMM patients refractory to...

Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA

$HORIZON update: Using melflufen to treat RRMM patients refractory to daratumumab and/or pomalidomide ( Prof Paul Richardson - Dana-Farber Cancer Institute, Boston, USA )$

PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin...

Michael Fuchs - University Hospital of Cologne, Cologne, Germany

PET after 2 cycles of ABVD in patients with early-stage favourable Hodgkin lymphoma ( Michael Fuchs - University Hospital of Cologne, Cologne, Germany )

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL

Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany

CLL12 trial: Ibrutinib in previously untreated, asymptomatic early-stage CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )

Chemoimmunotherapy or BTK inhibition for patients with CLL

Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany

Chemoimmunotherapy or BTK inhibition for patients with CLL ( Dr Othman Al-Sawaf - University of Cologne, Cologne, Germany )

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma

Dr Johannes Düll - University of Würzburg, Würzburg, Germany

MOR208 plus lenalidomide in r-r diffuse large B-cell lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )

Blinatumomab for relapsed/refractory Burkitt's lymphoma

Dr Johannes Düll - University of Würzburg, Würzburg, Germany

$Blinatumomab for relapsed/refractory Burkitt's lymphoma ( Dr Johannes Düll - University of Würzburg, Würzburg, Germany )$

Using bioinformatics and genomics to treat AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

Using bioinformatics and genomics to treat AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

The changing landscape of AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

The changing landscape of AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL

Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL ( Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany )

More from ecancer